Checkmate 067 - combined nivolumab and ipilimumab
Checkmate 067 - combined nivolumab and ipilimumab
Glycemia positively associated with prostate cancer mortality in non-diabetic men
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors
Durable responses to avelumab in patients with Merkel cell carcinoma
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses
Five-year follow-up of nivolumab in NSCLC
Mutations in cancer predisposition genes and risk for subsequent neoplasms
Final overall survival analysis of MONARCH 1
Redefining tamoxifen for breast cancer
Olaparib and temozolomide for relapsed small cell lung cancer
Treatment choices for HER2 amplified colorectal cancer
Final results of the HERACLES trial in HER2-amplified colorectal cancer